These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 10367046)

  • 1. Therapy of established postmenopausal osteoporosis with monofluorophosphate plus calcium: dose-related effects on bone density and fracture rate.
    Ringe JD; Kipshoven C; Cöster A; Umbach R
    Osteoporos Int; 1999; 9(2):171-8. PubMed ID: 10367046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Avoidance of vertebral fractures in men with idiopathic osteoporosis by a three year therapy with calcium and low-dose intermittent monofluorophosphate.
    Ringe JD; Dorst A; Kipshoven C; Rovati LC; Setnikar I
    Osteoporos Int; 1998; 8(1):47-52. PubMed ID: 9692077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial.
    Reginster JY; Meurmans L; Zegels B; Rovati LC; Minne HW; Giacovelli G; Taquet AN; Setnikar I; Collette J; Gosset C
    Ann Intern Med; 1998 Jul; 129(1):1-8. PubMed ID: 9652994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial of sodium fluoride (60 mg) +/- estrogen in postmenopausal osteoporotic vertebral fractures: increased vertebral fractures and peripheral bone loss with sodium fluoride; concurrent estrogen prevents peripheral loss, but not vertebral fractures.
    Gutteridge DH; Stewart GO; Prince RL; Price RI; Retallack RW; Dhaliwal SS; Stuckey BG; Drury P; Jones CE; Faulkner DL; Kent GN; Bhagat CI; Nicholson GC; Jamrozik K
    Osteoporos Int; 2002; 13(2):158-70. PubMed ID: 11908491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy.
    Meunier PJ; Sebert JL; Reginster JY; Briancon D; Appelboom T; Netter P; Loeb G; Rouillon A; Barry S; Evreux JC; Avouac B; Marchandise X
    Osteoporos Int; 1998; 8(1):4-12. PubMed ID: 9692071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of vertebral osteoporosis with disodium monofluorophosphate: comparison with sodium fluoride.
    Delmas PD; Dupuis J; Duboeuf F; Chapuy MC; Meunier PJ
    J Bone Miner Res; 1990 Mar; 5 Suppl 1():S143-7. PubMed ID: 2339624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
    Reginster JY; Felsenberg D; Pavo I; Stepan J; Payer J; Resch H; Glüer CC; Mühlenbacher D; Quail D; Schmitt H; Nickelsen T
    Osteoporos Int; 2003 Sep; 14(9):741-9. PubMed ID: 12827224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
    Liberman UA; Weiss SR; Bröll J; Minne HW; Quan H; Bell NH; Rodriguez-Portales J; Downs RW; Dequeker J; Favus M
    N Engl J Med; 1995 Nov; 333(22):1437-43. PubMed ID: 7477143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study.
    Alexandersen P; Riis BJ; Christiansen C
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3013-20. PubMed ID: 10487657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of monofluorophosphate to estrogen therapy in postmenopausal osteoporosis: a randomized controlled trial.
    Reid IR; Cundy T; Grey AB; Horne A; Clearwater J; Ames R; Orr-Walker BJ; Wu F; Evans MC; Gamble GD; King A
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2446-52. PubMed ID: 17440020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis.
    Riggs BL; Hodgson SF; O'Fallon WM; Chao EY; Wahner HW; Muhs JM; Cedel SL; Melton LJ
    N Engl J Med; 1990 Mar; 322(12):802-9. PubMed ID: 2407957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of nonrandomized trials with slow-release sodium fluoride with a randomized placebo-controlled trial in postmenopausal osteoporosis.
    Pak CY; Adams-Huet B; Sakhaee K; Bell NH; Licata A; Johnston C; Rubin B; Bonnick S; Piziak V; Graham H; Ballard J; Berger R; Fears W; Breslau N; Rubin C
    J Bone Miner Res; 1996 Feb; 11(2):160-8. PubMed ID: 8822339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of combined treatment with etidronate, nandrolone-decanoate and calcium on bone mineral density in postmenopausal women.
    Bolanca S; Korsić M; Dekanić D; Cvijetić S
    Acta Med Croatica; 1998; 52(3):159-63. PubMed ID: 9818438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
    Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
    Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In corticosteroid-treated respiratory diseases, monofluorophosphate increases lumbar bone density: a double-masked randomized study.
    Guaydier-Souquières G; Kotzki PO; Sabatier JP; Basse-Cathalinat B; Loeb G
    Osteoporos Int; 1996; 6(2):171-7. PubMed ID: 8704358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group.
    Hochberg MC; Ross PD; Black D; Cummings SR; Genant HK; Nevitt MC; Barrett-Connor E; Musliner T; Thompson D
    Arthritis Rheum; 1999 Jun; 42(6):1246-54. PubMed ID: 10366118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy.
    Sarkar S; Mitlak BH; Wong M; Stock JL; Black DM; Harper KD
    J Bone Miner Res; 2002 Jan; 17(1):1-10. PubMed ID: 11771654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone mineral density and vertebral fractures in men.
    Legrand E; Chappard D; Pascaretti C; Duquenne M; Rondeau C; Simon Y; Rohmer V; Basle MF; Audran M
    Osteoporos Int; 1999; 10(4):265-70. PubMed ID: 10692973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss.
    Reginster JY; Lecart MP; Richy F
    J Rheumatol Suppl; 2005 Sep; 76():21-5. PubMed ID: 16142847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).
    Ringe JD; Farahmand P; Schacht E; Rozehnal A
    Rheumatol Int; 2007 Mar; 27(5):425-34. PubMed ID: 17216477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.